Tikcro Technologies Announces 2016 Annual General Meeting

Wednesday, November 23, 2016 Corporate News J E 4

TEL AVIV, Israel, Nov. 23, 2016 /PRNewswire/ -- Tikcro Technologies Ltd. (OTCQX: TIKRF) today announced that its Annual General Meeting of Shareholders will be held on December 28, 2016 at 10:30 a.m. Israel time, at the office of the Company at 7 Sapir Street, Ness Ziona, Israel.

The agenda of the meeting is as follows:

(1)   election of Eric Paneth and Izhak Tamir to the Board of Directors;

(2)   re-approval of the existing compensation policy for officers and directors for a period of three years;

(3)   reappointment of Kost Forer Gabbay and Kasierer, a member of Ernst & Young Global, as independent auditors; and

(4)   consideration of audited financial statements for the year ended December 31, 2015.

Items 1 and 3 require the approval of a simple majority of the shares voted on the matter. Item 2 requires the affirmative vote of a majority of the shares present, in person or by proxy, and voting on the matter, provided that either (i) at least a majority of the shares of non-controlling shareholders and shareholders who do not have a personal interest in the resolution are voted in favor of the proposal, or (ii) the total number of shares of non-controlling shareholders and of shareholders who do not have a personal interest in the resolution voted against the proposal does not exceed two percent of the outstanding voting power in the Company. Item 4 will not involve a vote of the shareholders.

The record date for the meeting is November 28, 2016. Tikcro will send its shareholders of record a proxy statement describing the various matters to be voted upon at the meeting, along with a proxy card enabling them to indicate their vote on each matter.

About Tikcro Technologies:

Tikcro Technologies Ltd. (OTCQX: TIKRF) supports early stage development in growth areas, with a focus on biotechnology projects originated in Israeli academic centers. Tikcro is engaged with development of certain antibodies selected and verified in pre-clinical trials with a focus on antibodies binding to cancer immune modulators. For more information about Tikcro, visit Tikcro's website at

To view the original version on PR Newswire, visit:

SOURCE Tikcro Technologies Ltd.



You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
New Canadian investments in ALS research reflect g...
Medical Devices Leader Series: Top In Vitro Diagno...